Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery

Tamara Z. Vern-Gross, Julia A. Lawrence, L. Douglas Case, Kevin P. McMullen, J. Daniel Bourland, Linda J. Metheny-Barlow, Thomas L. Ellis, Stephen B. Tatter, Edward G. Shaw, James J. Urbanic, Michael D. Chan

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We investigate the variance in patterns of failure after Gamma Knife™ radiosurgery (GKRS) for patients with brain metastases based on the subtype of the primary breast cancer. Between 2000 and 2010, 154 breast cancer patients were treated with GKRS for brain metastases. Tumor subtypes were approximated based on hormone receptor (HR) and HER2 status of the primary cancer: Luminal A/B (HR+/HER2(-)); HER2 (HER2+/HR(-)); Luminal HER2 (HR+/HER2+), Basal (HR(-)/HER2(-)), and then based on HER2 status alone. The median follow-up period was 54 months. Kaplan-Meier method was used to estimate survival times. Multivariable analysis was performed using Cox regression models. Median number of lesions treated was two (range 1-15) with a median dose of 20 Gy (range 9-24 Gy). Median overall survival (OS) was 7, 9, 11 and 22 months for Basal, Luminal A/B, HER2, and Luminal HER2, respectively (p = 0.001), and was 17 and 8 months for HER2+ and HER(-) patients, respectively (p

Original languageEnglish (US)
Pages (from-to)381-388
Number of pages8
JournalJournal of Neuro-Oncology
Volume110
Issue number3
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Radiosurgery
Hormones
Breast Neoplasms
Neoplasm Metastasis
Brain
Survival
Therapeutics
Proportional Hazards Models
Neoplasms

Keywords

  • Brain metastases
  • Breast cancer
  • Failure
  • Radiosurgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Vern-Gross, T. Z., Lawrence, J. A., Case, L. D., McMullen, K. P., Bourland, J. D., Metheny-Barlow, L. J., ... Chan, M. D. (2012). Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. Journal of Neuro-Oncology, 110(3), 381-388. https://doi.org/10.1007/s11060-012-0976-3

Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. / Vern-Gross, Tamara Z.; Lawrence, Julia A.; Case, L. Douglas; McMullen, Kevin P.; Bourland, J. Daniel; Metheny-Barlow, Linda J.; Ellis, Thomas L.; Tatter, Stephen B.; Shaw, Edward G.; Urbanic, James J.; Chan, Michael D.

In: Journal of Neuro-Oncology, Vol. 110, No. 3, 12.2012, p. 381-388.

Research output: Contribution to journalArticle

Vern-Gross, TZ, Lawrence, JA, Case, LD, McMullen, KP, Bourland, JD, Metheny-Barlow, LJ, Ellis, TL, Tatter, SB, Shaw, EG, Urbanic, JJ & Chan, MD 2012, 'Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery', Journal of Neuro-Oncology, vol. 110, no. 3, pp. 381-388. https://doi.org/10.1007/s11060-012-0976-3
Vern-Gross, Tamara Z. ; Lawrence, Julia A. ; Case, L. Douglas ; McMullen, Kevin P. ; Bourland, J. Daniel ; Metheny-Barlow, Linda J. ; Ellis, Thomas L. ; Tatter, Stephen B. ; Shaw, Edward G. ; Urbanic, James J. ; Chan, Michael D. / Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. In: Journal of Neuro-Oncology. 2012 ; Vol. 110, No. 3. pp. 381-388.
@article{8232754ad230437ea278bc5e3676abe7,
title = "Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery",
abstract = "We investigate the variance in patterns of failure after Gamma Knife™ radiosurgery (GKRS) for patients with brain metastases based on the subtype of the primary breast cancer. Between 2000 and 2010, 154 breast cancer patients were treated with GKRS for brain metastases. Tumor subtypes were approximated based on hormone receptor (HR) and HER2 status of the primary cancer: Luminal A/B (HR+/HER2(-)); HER2 (HER2+/HR(-)); Luminal HER2 (HR+/HER2+), Basal (HR(-)/HER2(-)), and then based on HER2 status alone. The median follow-up period was 54 months. Kaplan-Meier method was used to estimate survival times. Multivariable analysis was performed using Cox regression models. Median number of lesions treated was two (range 1-15) with a median dose of 20 Gy (range 9-24 Gy). Median overall survival (OS) was 7, 9, 11 and 22 months for Basal, Luminal A/B, HER2, and Luminal HER2, respectively (p = 0.001), and was 17 and 8 months for HER2+ and HER(-) patients, respectively (p",
keywords = "Brain metastases, Breast cancer, Failure, Radiosurgery",
author = "Vern-Gross, {Tamara Z.} and Lawrence, {Julia A.} and Case, {L. Douglas} and McMullen, {Kevin P.} and Bourland, {J. Daniel} and Metheny-Barlow, {Linda J.} and Ellis, {Thomas L.} and Tatter, {Stephen B.} and Shaw, {Edward G.} and Urbanic, {James J.} and Chan, {Michael D.}",
year = "2012",
month = "12",
doi = "10.1007/s11060-012-0976-3",
language = "English (US)",
volume = "110",
pages = "381--388",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery

AU - Vern-Gross, Tamara Z.

AU - Lawrence, Julia A.

AU - Case, L. Douglas

AU - McMullen, Kevin P.

AU - Bourland, J. Daniel

AU - Metheny-Barlow, Linda J.

AU - Ellis, Thomas L.

AU - Tatter, Stephen B.

AU - Shaw, Edward G.

AU - Urbanic, James J.

AU - Chan, Michael D.

PY - 2012/12

Y1 - 2012/12

N2 - We investigate the variance in patterns of failure after Gamma Knife™ radiosurgery (GKRS) for patients with brain metastases based on the subtype of the primary breast cancer. Between 2000 and 2010, 154 breast cancer patients were treated with GKRS for brain metastases. Tumor subtypes were approximated based on hormone receptor (HR) and HER2 status of the primary cancer: Luminal A/B (HR+/HER2(-)); HER2 (HER2+/HR(-)); Luminal HER2 (HR+/HER2+), Basal (HR(-)/HER2(-)), and then based on HER2 status alone. The median follow-up period was 54 months. Kaplan-Meier method was used to estimate survival times. Multivariable analysis was performed using Cox regression models. Median number of lesions treated was two (range 1-15) with a median dose of 20 Gy (range 9-24 Gy). Median overall survival (OS) was 7, 9, 11 and 22 months for Basal, Luminal A/B, HER2, and Luminal HER2, respectively (p = 0.001), and was 17 and 8 months for HER2+ and HER(-) patients, respectively (p

AB - We investigate the variance in patterns of failure after Gamma Knife™ radiosurgery (GKRS) for patients with brain metastases based on the subtype of the primary breast cancer. Between 2000 and 2010, 154 breast cancer patients were treated with GKRS for brain metastases. Tumor subtypes were approximated based on hormone receptor (HR) and HER2 status of the primary cancer: Luminal A/B (HR+/HER2(-)); HER2 (HER2+/HR(-)); Luminal HER2 (HR+/HER2+), Basal (HR(-)/HER2(-)), and then based on HER2 status alone. The median follow-up period was 54 months. Kaplan-Meier method was used to estimate survival times. Multivariable analysis was performed using Cox regression models. Median number of lesions treated was two (range 1-15) with a median dose of 20 Gy (range 9-24 Gy). Median overall survival (OS) was 7, 9, 11 and 22 months for Basal, Luminal A/B, HER2, and Luminal HER2, respectively (p = 0.001), and was 17 and 8 months for HER2+ and HER(-) patients, respectively (p

KW - Brain metastases

KW - Breast cancer

KW - Failure

KW - Radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84871289935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871289935&partnerID=8YFLogxK

U2 - 10.1007/s11060-012-0976-3

DO - 10.1007/s11060-012-0976-3

M3 - Article

C2 - 23001361

AN - SCOPUS:84871289935

VL - 110

SP - 381

EP - 388

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -